Brian G. Feagan

P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study

BACKGROUND: True North is a phase 3, randomized, double-blind, placebo-controlled trial conducted at 285 sites in 30 countries (NCT02435992). Treatment with on...

Stephen B. Hanauer , MD;

Michael Silver ;

Brian G. Feagan ;

Raymond Cross , MD;

David Hudesman , MD;

Douglas Wolf ;

Millie D. Long , MD, MPH;

Subrata Ghosh ;

AnnKatrin Petersen ;

Marc Pondel ;

12/15/2021

A Practical Approach to Anti-Integrins in IBD 2020

Brian G. Feagan ;

12/14/2019

Correlation Between Histologic Indices and Ulcerative Colitis Activity Measures Among Patients in the HICKORY (Etrolizumab) Open-Label Induction Cohort

BACKGROUND: Cross-sectional studies in ulcerative colitis (UC) have shown at best a moderate association between histologic and clinical measures of disease activity, but few longitudinal...

Brian G. Feagan ;

David T. Rubin , MD;

Rish Pai ;

Audrey Boruvka ;

Young Oh ;

Alexis Scherl ;

Astrid Scalori ;

Pablo Arrisi ;

Laurent Peyrin-Biroulet ;

Swati Tole ;

12/13/2019

Efficacy and Safety of Icanbelimod (CBP-307) in Adults With Moderate to Severe Ulcerative Colitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

1 Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China; 2 The Affiliated Hospital of Qingdao University, Qingdao, Qingda...

Feng Xu ;

Jiaming Qian ;

Zibin Tian ;

Yanqing Li ;

Fangyu Wang ;

Xiaolan Zhang ;

Hong Yang ;

David T. Rubin , MD;

Jiawang Guo ;

Wubin Pan ;

Brian G. Feagan ;

Raul Collazo ;